IDH2 and astrocytoma (excluding glioblastoma): Notably, IDH-mutant astrocytomas with homozygous CDKN2A deletion are now considered WHO grade 4 regardless of histologic features [2, 18], although numerous other mutations, specific copy number variants, and other molecular features have been suggested as relevant to prognosis and potentially tumor grade [21].